CCO Treatment Updates
Ovarian Cancer—Recent Developments in the Standard of Care and Emerging Options
Virtual Presentations
Ovarian Cancer Frontline Management—IP and Maintenance Therapy and Rising CA-125: To Treat or Not to Treat?
|
Program Director: Bradley J. Monk, MD, FACOG, FACS
 
- J. Tate Thigpen, MD
- Thomas J. Herzog, MD
|
|
|
This presentation consists of 2 talks. In the first talk, J. Tate Thigpen, MD, discusses the use of intraperitoneal and maintenance therapies in the frontline management of ovarian cancer; in the second talk, Thomas J. Herzog, MD, explores the controversies surrounding the role of rising CA-125 levels in ovarian cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate the role of intraperitoneal chemotherapy in the frontline management of ovarian cancer
- Interpret the use of maintenance therapy in the frontline treatment of ovarian cancer
- Analyze the controversies related to the role of rising CA-125 levels in determining treatment for ovarian cancer patients
- Evaluate the use of CA-125 testing in managing patients with ovarian cancer
|
Slideset: Ovarian Cancer Frontline Management—IP and Maintenance Therapy and Rising CA-125: To Treat or Not to Treat?
 |
|
Download slides on IP and maintenance therapy in ovarian cancer and of the role of CA-125 in this disease for use in your noncommercial presentations.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.81 MB
| Date posted: 8/5/2009
|
Platinum-Resistant Recurrent Ovarian Cancer and The Role of Platinum Doublets in Platinum-Sensitive Recurrent Disease
|
Program Director: Bradley J. Monk, MD, FACOG, FACS
- Bradley J. Monk, MD, FACOG, FACS
- J. Tate Thigpen, MD
|
|
|
This presentation consists of 2 separate talks. In the first, Bradley J. Monk, MD, FACOG, FACS, explores current and novel treatment approaches for platinum-resistant recurrent ovarian cancer. In the second talk, J. Tate Thigpen, MD, discusses the role of platinum doublets in the management of patients with platinum-sensitive recurrent ovarian cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare the current treatment options for ovarian cancer in patients with platinum-resistant recurrent disease
- Analyze recent data from ongoing phase III trials investigating novel agents and approaches in platinum-resistant recurrent ovarian cancer
- Evaluate the use of platinum doublets in platinum-sensitive recurrent ovarian cancer
|
Slideset: Platinum-Resistant Recurrent Ovarian Cancer and The Role of Platinum Doublets in Platinum-Sensitive Recurrent Disease
 |
|
Download slides on treatment options in platinum-resistant recurrent ovarian cancer and on the use of platinum doublets in treating patients with platinum-sensitive disease.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.45 MB
| Date posted: 8/10/2009
|
Platinum-Sensitive Recurrent Ovarian Cancer (Nonplatinum Doublets) and Platinum-Sensitive Recurrent Disease: Role of Biologics and Secondary Cytoreduction
|
Program Director: Bradley J. Monk, MD, FACOG, FACS
- Bradley J. Monk, MD, FACOG, FACS
- Thomas J. Herzog, MD
|
|
|
This virtual presentation consists of 2 talks in platinum-sensitive recurrent ovarian cancer. Bradley J. Monk, MD, FACOG, FACS, discusses the role of nonplatinum doublets in the first talk, and Thomas J. Herzog, MD, explores biologics and secondary cytoreduction in the second talk.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Appraise the controversies in treating patients with platinum-sensitive recurrent ovarian cancer
- Analyze recent data supporting the use of nonplatinum doublets in the management of platinum-sensitive recurrent ovarian cancer
- Interpret the role of secondary cytoreduction in treating ovarian cancer patients with platinum-sensitive disease
- Compare the clinical trials investigating the use of biologic agents in the management of platinum-sensitive ovarian cancer
|
Slideset: Platinum-Sensitive Recurrent Ovarian Cancer (Nonplatinum Doublets) and Platinum-Sensitive Recurrent Disease: Role of Biologics and Secondary Cytoreduction
 |
|
View slides on recent data on the use of nonplatinum doublets in platinum-sensitive recurrent ovarian cancer and on the roles of biologic agents and secondary cytoreduction in recurrent disease.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.61 MB
| Date posted: 8/11/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|